Binge-eating disorder (BED), a public health problem associated with psychopathological symptoms and obesity and possibly with metabolic syndrome, lacks approved pharmacotherapies.
To examine the efficacy and safety of lisdexamfetamine dimesylate, a dextroamphetamine prodrug, to treat moderate to severe BED.
Design, Setting, and Participants
JAMA Psychiatry. Published online January 14, 2015. doi:10.1001/jamapsychiatry.2014.2162